91 related articles for article (PubMed ID: 12722404)
41. [The assessment of the dependence between antigen CA 125 and nicotinism in patients with benign ovarian tumors including endometrial cysts].
Posadzka E; Jach R; Babczyk D; Knafel A; Pityński K
Przegl Lek; 2014; 71(6):319-22. PubMed ID: 25344972
[TBL] [Abstract][Full Text] [Related]
42. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis.
Tsukishiro S; Suzumori N; Nishikawa H; Arakawa A; Suzumori K
Gynecol Oncol; 2005 Feb; 96(2):516-9. PubMed ID: 15661245
[TBL] [Abstract][Full Text] [Related]
43. Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level.
Obeidat B; Latimer J; Crawford R
Gynecol Obstet Invest; 2004; 57(3):153-6. PubMed ID: 14726621
[TBL] [Abstract][Full Text] [Related]
44. TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms.
Harłozinska A; Sedlaczek P; Van Dalen A; Rozdolski K; Einarsson R
Anticancer Res; 1997; 17(6D):4473-8. PubMed ID: 9494553
[TBL] [Abstract][Full Text] [Related]
45. High serum levels of follistatin in patients with ovarian cancer.
Ren P; Chen FF; Liu HY; Cui XL; Sun Y; Guan JL; Liu ZH; Liu JG; Wang YN
J Int Med Res; 2012; 40(3):877-86. PubMed ID: 22906260
[TBL] [Abstract][Full Text] [Related]
46. Preoperative value of CA 125 as a reflection of tumor grade in epithelial ovarian cancer.
But I; Gorisek B
Gynecol Oncol; 1996 Nov; 63(2):166-72. PubMed ID: 8910622
[TBL] [Abstract][Full Text] [Related]
47. Levels of soluble intercellular adhesion molecule-1 and total sialic acid in serum of patients with colorectal cancer.
Basoglu M; Yildirgan MI; Taysi S; Yilmaz I; Kiziltunc A; Balik AA; Celebi F; Atamanalp SS
J Surg Oncol; 2003 Jul; 83(3):180-4. PubMed ID: 12827689
[TBL] [Abstract][Full Text] [Related]
48. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy.
Tuxen MK; Sölétormos G; Dombernowsky P
Br J Cancer; 2001 May; 84(10):1301-7. PubMed ID: 11355938
[TBL] [Abstract][Full Text] [Related]
49. Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression.
Hirai S; Kageshita T; Kimura T; Tsujisaki M; Imai K; Wakamatsu K; Ito S; Ono T
Melanoma Res; 1997 Feb; 7(1):58-62. PubMed ID: 9067966
[TBL] [Abstract][Full Text] [Related]
50. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer.
Cooper BC; Ritchie JM; Broghammer CL; Coffin J; Sorosky JI; Buller RE; Hendrix MJ; Sood AK
Clin Cancer Res; 2002 Oct; 8(10):3193-7. PubMed ID: 12374688
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of soluble tumour necrosis factor alpha receptors p55 and p75 in ovarian cancer patients.
Opala T; Rzymski P; Wilczak M; Woźniak J
Eur J Gynaecol Oncol; 2005; 26(1):43-6. PubMed ID: 15754999
[TBL] [Abstract][Full Text] [Related]
52. Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer.
Tuxen MK; Sölétormos G; Rustin GJ; Nelstrop AE; Dombernowsky P
Scand J Clin Lab Invest; 2000 Dec; 60(8):713-21. PubMed ID: 11218154
[TBL] [Abstract][Full Text] [Related]
53. Soluble intercellular adhesion molecule-1 as a prognostic marker for stage II colorectal cancer patients.
Toiyama Y; Miki C; Inoue Y; Okugawa Y; Koike Y; Yokoe T; Tanaka K; Kusunoki M
Ann Surg Oncol; 2008 Jun; 15(6):1617-24. PubMed ID: 18368454
[TBL] [Abstract][Full Text] [Related]
54. [Usefulness of osteopontin (OPN) determinations in ovarian cancer patients who underwent first-line chemotherapy].
Mrochem-Kwarciak J; Mrochen-Domin I; Wojcieszek A; Deja R; Chmura A; Masłyk B; Nowara E; Kaleta B; Kołosza Z; Bartnik W
Ginekol Pol; 2011 Dec; 82(12):911-7. PubMed ID: 22384627
[TBL] [Abstract][Full Text] [Related]
55. [Usefulness of clinical evaluation for the level of CA-125 antigen and ultrasonographic color Doppler examination in diagnosis of ovarian tumor].
Czekierdowski A; Zrubek H; Sikorski M; Wiktor H; Józefczak M; Stachowicz N
Ginekol Pol; 1996 Nov; 67(11):552-6. PubMed ID: 9289441
[TBL] [Abstract][Full Text] [Related]
56. Tissue AP-2gamma and Oct-3/4, and serum CA 125 as diagnostic and prognostic markers of malignant ovarian germ cell tumors.
Salonen J; Leminen A; Stenman UH; Butzow R; Heikinheimo M; Heikinheimo O
Tumour Biol; 2008; 29(1):50-6. PubMed ID: 18497549
[TBL] [Abstract][Full Text] [Related]
57. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer.
Kobayashi H; Terao T; Kawashima Y
J Clin Oncol; 1991 Jun; 9(6):983-7. PubMed ID: 1851822
[TBL] [Abstract][Full Text] [Related]
58. Soluble intercellular adhesion molecule 1 (sICAM-1) and malignant melanoma.
Viac J; Gueniche A; Faure M; Claudy A
Cancer Lett; 1993 Aug; 72(3):191-4. PubMed ID: 8104685
[TBL] [Abstract][Full Text] [Related]
59. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.
Badgwell D; Lu Z; Cole L; Fritsche H; Atkinson EN; Somers E; Allard J; Moore RG; Lu KH; Bast RC
Gynecol Oncol; 2007 Sep; 106(3):490-7. PubMed ID: 17532030
[TBL] [Abstract][Full Text] [Related]
60. [Evaluation of serum sICAM-1 and sVCAM-1 concentration in patient at risk of preterm delivery].
Urban R; Lemancewicz A; Urban J; Kretowska M
Ginekol Pol; 2003 Oct; 74(10):1325-8. PubMed ID: 14669438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
